This is Vol.76 Newsletter for June 2026.
June 2026 highlighted a more complex healthcare and biopharma landscape shaped by innovation, market transition, and evolving regulation. Competition for next-generation drug platforms intensified, product turnover accelerated across key therapeutic markets, new options emerged in rare disease treatment, and medical devices faced growing pressure to strengthen global regulatory and commercialization pathways. At the same time, second-generation medical AI is moving beyond detection into treatment planning and decision support, while international joint reviews and expanding open innovation reflect a broader shift toward execution-driven global competitiveness.